Related Experiment Video
Updated: Jul 15, 2026

Preparing T Cell Growth Factor from Rat Splenocytes
Published on: October 31, 2007
Adenoviral-mediated inhibition of connective tissue growth factor in Rat-2 cells
Jennifer L Winkler1, Mamdouh H Kedees, Gladys Teitelman
1Department of Anatomy and Cell Biology, State University of New York (SUNY) Downstate Medical Center, Room 2-94, 450 Clarkson Avenue, Brooklyn, NY 11203, USA.
Abstract:
Connective tissue growth factor (CTGF) is a profibrotic factor shown to induce extracellular matrix production and angiogenesis, two processes involved in the development of diabetic retinopathy (DR). In this study we tested the effect of a recombinant adenovirus encoding for a CTGF antisense oligonucleotide (rAdASO) on the levels of transforming growth factor-beta (TGF-beta) induced expression of CTGF in Rat-2 fibroblasts. Using semi-quantitative RT-PCR, there was a 2-fold increase in CTGF message induced by TGF-beta. Western blot and immunocytochemical analyses revealed a significant increase in CTGF protein level. This upregulation of CTGF by TGF-beta was inhibited by infection with rAdASO. These findings indicate that infection of the Rat-2 cells with rAdASO was effective in decreasing TGF-beta-induced CTGF expression. These results indicate that this viral vector might have therapeutic potential to control elevated CTGF levels that occur in DR.
Insights
A novel viral vector effectively reduced connective tissue growth factor (CTGF) expression in lab studies. This suggests potential for treating diabetic retinopathy (DR) by controlling CTGF levels.
Area of Science:
- Ophthalmology
- Molecular Biology
- Genetics
Background:
- Connective tissue growth factor (CTGF) promotes fibrosis and angiogenesis, key factors in diabetic retinopathy (DR) development.
- Elevated CTGF levels are implicated in the pathogenesis of DR.
Purpose of the Study:
- To investigate the therapeutic potential of a recombinant adenovirus carrying a CTGF antisense oligonucleotide (rAdASO).
- To assess the ability of rAdASO to inhibit transforming growth factor-beta (TGF-beta)-induced CTGF expression in fibroblasts.
Main Methods:
- Utilized semi-quantitative RT-PCR to measure CTGF messenger RNA (mRNA) levels.
- Employed Western blot and immunocytochemistry to quantify CTGF protein expression.
- Infected Rat-2 fibroblasts with rAdASO to evaluate its inhibitory effect on TGF-beta-induced CTGF.
Main Results:
- TGF-beta significantly increased CTGF mRNA and protein levels (2-fold increase in mRNA).
- Infection with rAdASO effectively inhibited the TGF-beta-induced upregulation of CTGF.
- Demonstrated successful reduction of CTGF expression by the rAdASO viral vector in vitro.
Conclusions:
- The rAdASO viral vector demonstrates efficacy in decreasing TGF-beta-induced CTGF expression in fibroblasts.
- This approach holds therapeutic promise for managing elevated CTGF levels in diabetic retinopathy.
- Further research may validate rAdASO as a treatment strategy for DR.
Related Concept Videos
TGF - β Signaling Pathway
Inhibitors of Virion Maturation and Assembly
